Riociguat 2.5 mg - Resultados da pesquisa

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

adempas 2.5mg film-coated tablet

bayer co. (malaysia) sdn. bhd. - riociguat -

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 0.5mg - film coated tablet - 0.5 mg - active: riociguat 0.5mg excipient: crospovidone hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 1.5mg - film coated tablet - 1.5 mg - active: riociguat 1.5mg excipient: crospovidone hyprolose hypromellose iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

adempas

bayer new zealand limited - riociguat 2.5mg - film coated tablet - 2.5 mg - active: riociguat 2.5mg excipient: crospovidone hyprolose hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified water sodium laurilsulfate titanium dioxide - pulmonary arterial hypertension adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, iii or iv symptoms.